Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for MolPort-002-137-856

    Client Email Product

    MolPort-002-137-856

    APIs // Active Pharmaceutical Ingredients

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    30
    US DMFs Filed

    US DMFs Filed

    8
    CEP/COS Certifications

    CEP/COS Certifications

    5
    JDMFs Filed

    JDMFs Filed

    5
    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    19
    API REF. PRICE (USD / KG)
    24

    API Market Place

    73
    INTERMEDIATES
    1
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    35
    Europe

    Europe

    31
    Canada

    Canada

    7
    Australia

    Australia

    0

    South Africa

    South Africa

    114
    Uploaded Dossiers

    Uploaded Dossiers

    111
    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    0

    FDF Market Place

    8
    EXCIPIENTS
    402
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    4

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    4

    News

    31
    REF STANDARD

    EDQM

    2

    USP

    1

    JP

    2

    Other Listed Suppliers

    14
    SERVICES

    0

    left grey arrow
    right gray arrow
    • FOR SOLUTION;INTRAVENOUS - 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL
    • SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML
    • SOLUTION;INTRAVENOUS - 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML
    • INJECTABLE;INTRAVENOUS - 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL
    • INJECTABLE;INJECTION - 20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML;0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML
    Full View ScreenFull Screen View
    Akums to empower mothers with Doxylamine + Pyridoxine extended-release tablets
    Akums to empower mothers with Doxylamine + Pyridoxine extended-release tablets

    https://www.indianpharmapost.com/news/akums-to-empower-mothers-with-doxylamine-pyridoxine-extended-release-tablets-for-severe-morning-sickness-15073

    INDIAN PHARMA POST
    28 Dec 2023
    Share Share
    Bionpharma's Generic Doxylamine Succinate, Pyridoxine Hydrochloride Receives Approval in the U.S.
    Bionpharma's Generic Doxylamine Succinate, Pyridoxine Hydrochloride Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217000

    FDA
    04 Aug 2023
    Share Share
    Enforcement Report - Week Of June 01, 2022
    Enforcement Report - Week Of June 01, 2022

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-01-2022-1654158193.pdf

    FDA
    01 Jun 2022
    Share Share
    Enforcement Report - Week of February 9, 2022
    Enforcement Report - Week of February 9, 2022

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-9-2022-1644385243.pdf

    FDA
    09 Feb 2022
    Share Share
    Emery Pharma Files FDA Citizen Petition on VitB6 Toxicity & Urges Warning Label
    Emery Pharma Files FDA Citizen Petition on VitB6 Toxicity & Urges Warning Label

    https://www.prnewswire.com/news-releases/emery-pharma-files-an-fda-citizen-petition-on-vitamin-b6-toxicity-and-urges-warning-label-301380933.html

    PRNEWSWIRE
    20 Sep 2021
    Share Share
    FDA to Study Perceptions of Instagram Influencers and Their Disclosures
    FDA to Study Perceptions of Instagram Influencers and Their Disclosures

    https://www.raps.org/news-and-articles/news-articles/2020/1/fda-to-study-perceptions-of-instagram-influencers

    Zachary Brennan RAPS
    27 Jan 2020
    Share Share
    Class 4 Medicine Defect Information: Xonvea 10 mg/10 mg gastro-resistant tablets
    Class 4 Medicine Defect Information: Xonvea 10 mg/10 mg gastro-resistant tablets

    https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-xonvea-10-mg-10-mg-gastro-resistant-tablets-mdr-025-10-19

    MHRA
    17 Oct 2019
    Share Share
    Enforcement Report - Week of August 14, 2019
    Enforcement Report - Week of August 14, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-14-2019-1565765849.pdf

    FDA
    14 Aug 2019
    Share Share
    Enforcement Report - Week of June 19, 2019
    Enforcement Report - Week of June 19, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-19-2019-1560925761.pdf

    FDA
    19 Jun 2019
    Share Share
    NPPA fixes retail prices of 22 formulations under DPCO, 2013
    NPPA fixes retail prices of 22 formulations under DPCO, 2013

    http://pharmabiz.com/ArticleDetails.aspx?aid=115527&sid=1

    PHARMABIZ
    06 May 2019
    Share Share
    Enforcement Report for Week of February 20, 2019
    Enforcement Report for Week of February 20, 2019

    https://www.pharmacompass.com/pdf/news/Enforcement-Report-for-Week-of-February-20-2019-1550644123.pdf

    FDA
    20 Feb 2019
    Share Share
    Enforcement Report - Week of January 9, 2019
    Enforcement Report - Week of January 9, 2019

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-9-2019-1547012578.pdf

    FDA
    09 Jan 2019
    Share Share
    Enforcement Report - Week of November 7, 2018
    Enforcement Report - Week of November 7, 2018

    https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-November-7-2018-1541578996.pdf

    FDA
    07 Nov 2018
    Share Share
    Updated List of New Paragraph IV Patent Certifications - Oct 22
    Updated List of New Paragraph IV Patent Certifications - Oct 22

    https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM293268.pdf

    FDA
    01 Nov 2018
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Bonjesta 209661 (Doxylamine Succinate and Pyridoxine Hydrochloride) Extended-release Tablets
    FDA Confirms Paragraph IV Patent Challenge of Bonjesta 209661 (Doxylamine Succinate and Pyridoxine Hydrochloride) Extended-release Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-cubicin-rf-21572-daptomycin-for-injection-1541062857.pdf

    FDA
    01 Nov 2018
    Share Share
    A drug maker paid Kim Kardashian $500,000 for a few social media posts!
    A drug maker paid Kim Kardashian $500,000 for a few social media posts!

    https://www.statnews.com/pharmalot/2018/07/10/kim-kardashian-morning-sickness-instagram/

    Ed Silverman STAT NEWS
    11 Jul 2018
    Share Share
    Cipla, Unitaid join hands to reduce HIV drug price
    Cipla, Unitaid join hands to reduce HIV drug price

    https://www.biospectrumasia.com/news/28/11065/cipla-unitaid-join-hands-to-reduce-hiv-drug-price.html

    BIOSPECTRUM
    11 Jun 2018
    Share Share
    Duchesnay USA Announces Launch Bonjesta®doxylamine succinate, pyridoxine HCL)
    Duchesnay USA Announces Launch Bonjesta®doxylamine succinate, pyridoxine HCL)

    https://www.prnewswire.com/news-releases/duchesnay-usa-announces-launch-of-bonjesta-doxylamine-succinate---pyridoxine-hydrochloride-in-the-united-states-300620521.html

    PR NEWSWIRE
    02 Apr 2018
    Share Share
    Report calls into question effectiveness of pyridoxine-doxylamine
    Report calls into question effectiveness of pyridoxine-doxylamine

    https://www.europeanpharmaceuticalreview.com/news/71835/effectiveness-pyridoxine-doxylamine/

    EU PHARMACEUTICAL
    17 Jan 2018
    Share Share
    Par Pharm’s Generic Doxylamine Succinate; Pyridoxine HCL Receives Approval In US
    Par Pharm’s Generic Doxylamine Succinate; Pyridoxine HCL Receives Approval In US

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208518

    FDA
    12 Dec 2017
    Share Share
    Kim Kardashian flouts FDA warning AGAIN to promote 'dangerous' sickness pill
    Kim Kardashian flouts FDA warning AGAIN to promote 'dangerous' sickness pill

    http://www.dailymail.co.uk/health/article-4740842/Kim-Kardashian-flouts-FDA-warning-promote-pill.html

    DAILYMAIL
    28 Jul 2017
    Share Share
    Laboratoires Colba Inc. Recalls Enerforce Total
    Laboratoires Colba Inc. Recalls Enerforce Total

    http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/62304r-eng.php

    HEALTH CANADA
    22 Feb 2017
    Share Share
    Evidence That Prescription Drug For Morning Sickness Works Is Lacking
    Evidence That Prescription Drug For Morning Sickness Works Is Lacking

    http://www.forbes.com/sites/ritarubin/2017/01/31/guidelines-recommend-it-but-evidence-that-prescription-drug-for-morning-sickness-works-is-lacking/#5d7f507015ed

    Rita Rubin FORBES
    31 Jan 2017
    Share Share
    Research Data, Missing for Decades, Raise Concerns on Morning Sickness Drug
    Research Data, Missing for Decades, Raise Concerns on Morning Sickness Drug

    https://www.statnews.com/2017/01/04/morning-sickness-diclegis-bendectin/

    IVAN ORANSKY STAT
    05 Jan 2017
    Share Share
    Actavis Receives FDA Approval for Doxylamine Succinate
    Actavis Receives FDA Approval for Doxylamine Succinate

    https://www.pharmacompass.com/pdf/news/actavis-receives-fda-approval-for-doxylamine-succinate-1472292974.pdf

    FDA
    19 Aug 2016
    Share Share
    Kim Kardashian posts drug’s side effects after FDA warning
    Kim Kardashian posts drug’s side effects after FDA warning

    http://nypost.com/2015/08/31/kim-kardashian-posts-drugs-side-effects-on-instagram-after-fda-warning/

    Post Staff Report NEW YORK POST
    01 Sep 2015
    Share Share
    Duchesnay USA Publishes Corrective Messaging through Kim Kardashian’s Social Media Accounts in Response to FDA’s Request
    Duchesnay USA Publishes Corrective Messaging through Kim Kardashian’s Social Media Accounts in Response to FDA’s Request

    http://www.multivu.com/players/English/7610451-diclegis-corrective-messaging/

    DUCHESNAY USA
    31 Aug 2015
    Share Share
    Anvisa suspends Dexadoze manufactured by Laboratorio Teuto Brasileiro S / A
    Anvisa suspends Dexadoze manufactured by Laboratorio Teuto Brasileiro S / A

    http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/anvisa+determina+recolhimento+e+suspensao+do+medicamento+dexadoze

    ANVISA
    11 Jun 2015
    Share Share
    Advanced Physician Solutions, Inc. initiates Class II recall of Nanpyridoxine due to Lack of Assurance of Sterility
    Advanced Physician Solutions, Inc. initiates Class II recall of Nanpyridoxine due to Lack of Assurance of Sterility

    http://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?action=select&recall_number=D-1102-2015&w=06032015&lang=eng

    FDA
    16 May 2015
    Share Share
    Diclegis® For Morning Sickness Now Available In Puerto Rico
    Diclegis® For Morning Sickness Now Available In Puerto Rico

    http://www.multivu.com/players/English/7487651-diclegis-available-for-morning-sickness/

    Press Release DUCHESNAY USA
    09 Apr 2015
    Share Share
    New technique determines which patients with homocystinuria will respond
    New technique determines which patients with homocystinuria will respond

    https://www.sciencedaily.com/releases/2012/04/120409103251.htm

    SCIENCE DAILY
    09 Apr 2012
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search